Significant Ownership of Two Seas Capital LP
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Two Seas Capital LP focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Sina Toussi - Sina Toussi/Managing Member of Two Seas Capital GP LLC, its general partner
- Manager location
- Rye, NY
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Two Seas Capital LP with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from Two Seas Capital LP
Significant Ownership of Two Seas Capital LP
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| OMEX | ODYSSEY MARINE EXPLORATION INC | Common Stock, par value $0.0001 per share | 10% | $4,814,822 | +$635,048 | 5,857,448 | +15% | Two Seas Capital LP | 08 Apr 2026 |
| PAVM | PAVmed Inc. | Common Stock, $0.001 par value per share | 10% | $157,733 | 657,219 | Two Seas Capital LP | 31 Mar 2026 | ||
| GCI | Gannett Co., Inc. | Common Stock, par value $0.01 per share | 9.6% | $58,565,965 | +$12,183,500 | 14,180,621 | +26% | Two Seas Capital LP | 30 Sep 2025 |
| ABUS | Arbutus Biopharma Corporation | Common Shares, without par value | 9.4% | $79,797,435 | +$25,664,056 | 18,557,543 | +47% | Two Seas Capital LP | 31 Mar 2026 |
| CLMT | Calumet, Inc. | Common Stock, par value $0.01 per share | 9.3% | $161,073,775 | +$26,765,794 | 8,098,229 | +20% | Two Seas Capital LP | 31 Dec 2025 |
| MDRX | Veradigm Inc. | Common Stock, par value $0.01 per share | 6.9% | $36,229,165 | +$7,986,025 | 7,469,931 | +28% | Two Seas Capital LP | 31 Dec 2025 |
| NKTR | NEKTAR THERAPEUTICS | Common Stock, $0.0001 par value | 6.8% | $144,979,172 | 1,959,178 | Two Seas Capital LP | 31 Mar 2026 | ||
| INDV | INDIVIOR PLC | Ordinary Shares, $0.50 nominal value per share | 5% | $203,438,218 | -$27,837,500 | 6,211,854 | -12% | Two Seas Capital LP | 23 Dec 2025 |
| ESPR | Esperion Therapeutics, Inc. | Common Stock, par value $0.001 per share | 4.7% | $25,836,769 | -$543,915 | 9,749,724 | -2.1% | Two Seas Capital LP | 30 Sep 2025 |
| CORZ | Core Scientific, Inc. | Common Stock, par value $0.00001 per share | 4.4% | $209,212,279 | -$58,852,640 | 13,984,778 | -22% | Two Seas Capital LP | 23 Apr 2026 |
| ADAP | Adaptimmune Therapeutics PLC | Ordinary Shares, par value GBP 0.001 per share | 0% | $0 | -$17,612,947 | 0 | -100% | Two Seas Capital LP | 30 Sep 2025 |
| AVDL | AVADEL PHARMACEUTICALS PLC | Ordinary Shares, nominal value $0.01 per share | 0% | $0 | -$132,210,990 | 0 | -100% | Two Seas Capital LP | 31 Dec 2025 |
Schedules 13D/G Reported by Two Seas Capital LP:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.